INmune Bio: NK Cell Therapy INKmune For mCRPC Is Another Shot On Goal
INmune Bio's initial results from cohort 1 of the phase I/II CaRe PC trial, using INKmune for the treatment of patients with mCRPC released; Additional results from higher cohorts expected throughout 2025. It is said that the global metastatic …